Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia: A Population-Based Nested Case-Control Study
J Clin Psychiatry 2010;71(2):103-108
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Concomitant prescription of more than 1 antipsychotic agent (antipsychotic polypharmacy) in the treatment of schizophrenia is prevalent, although monotherapy is generally
recommended. Mortality from natural causes
is markedly increased in schizophrenia, and
the role of polypharmacy remains controversial. The objective was to investigate if antipsychotic polypharmacy is associated with the excess mortality from natural causes among patients with schizophrenia.
Method: A population-based nested
case-control study was conducted using patient data from January 1, 1996, to December 31, 2005,
obtained from central Danish registers. From the study population of 27,633 patients with ICD-8– and ICD-10–diagnosed schizophrenia or other mainly nonaffective psychoses, aged 18–53 years, we identified 193 cases who died of natural causes within a 2-year period and 1,937 age- and sex-matched controls. Current drug use was defined
as at least 1 prescription filled within 90 days before the date of death or the index date. The data were analyzed by conditional logistic regression.
Results: Risk of natural death did not increase with the number of concurrently used antipsychotic agents compared with antipsychotic monotherapy (no antipsychotics: adjusted
odds ratio [OR] = 1.48 [95% CI, 0.89–2.46]; 2 antipsychotics: OR = 0.91 [95% CI, 0.61–1.36]; 3 or more antipsychotics: OR = 1.16 [95% CI, 0.68–2.00]). Current use of benzodiazepine derivatives with long elimination half-lives (more than 24 hours) was associated with increased risk of natural death in patients with schizophrenia treated with antipsychotics (OR = 1.78 [95% CI, 1.25–2.52]).
Conclusions: Antipsychotic polypharmacy did not contribute to the excess mortality from natural causes in middle-aged patients with schizophrenia. The detected increased risk of death associated with benzodiazepines with long elimination half-lives calls for further clarification.
Submitted: October 23, 2008; accepted January 2, 2009.
Online ahead of print: November 3, 2009.
Corresponding author: Lone Baandrup, MD, Centre for Neuropsychiatric Schizophrenia Research, Psychiatric Centre Glostrup, Copenhagen University Hospital, Glostrup, Nordre Ringvej 29-67, DK-2600 Glostrup, Denmark (email@example.com).